Value-based Care And Digital Automation Will Expand Future Opportunities

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

07 May 25

Updated

09 Dec 25

Views

46

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-65.2%

7D

-3.6%

Loading

1Y

-65.2%

7D

-3.6%

You can edit this narrative until Dec 10 12:05 PM. Then, changes will post as Updates.

Author's Valuation

US$10.1861.0% undervalued

AnalystConsensusTarget Fair Value

Shared on 09 Dec 25

Fair value Decreased 7.77%

EVH: Contract Wins And AI Initiatives Will Drive Future Margin Expansion

Analysts have modestly reduced their price expectations for Evolent Health, with the fair value estimate easing by about $0.86 per share as they factor in lower target multiples and a slightly softer growth outlook, while still expressing confidence in the company’s long term EBITDA and margin expansion potential. Analyst Commentary Analysts remain constructive on Evolent Health’s long term setup, highlighting a growing contract base and clearer visibility into future revenue, but they are recalibrating expectations to reflect a more gradual earnings ramp and policy related uncertainty.

Shared on 25 Nov 25

Fair value Decreased 17%

EVH: Contract Pipeline Expansion And AI Initiatives Will Drive Margin Expansion

Analysts have revised Evolent Health's fair value estimate downward from $13.35 to $11.04 per share. This revision reflects tempered near-term growth expectations and ongoing sector uncertainties, although there remains optimism about the company's long-term margin and contract pipeline.

Shared on 10 Nov 25

Fair value Decreased 14%

EVH: Leadership Changes And Oncology Alliance Will Drive Stronger Performance

Analysts have revised their price target for Evolent Health downward from $15.46 to $13.35 per share. This change is attributed to updated assumptions regarding growth rates and profitability.

AnalystConsensusTarget Fair Value

US$10.18

61.0% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

13.68%

Healthtech revenue growth rate

12.65%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

12.50%

Calculation

US$213.93m

Earnings '28

x

6.84x

PE Ratio '28

=

US$1.46b

Market Cap '28

US$1.46b

Market Cap '28

/

101.85m

No. shares '28

=

US$14.37

Share Price '28

US$14.37 Share Price '28

Discounted to 2025 @ 12.50% p.a.

=

US$10.09

Fair Value '25